Sana Biotechnology Announces Positive Diabetes Study Results

Sana Biotechnology ( (SANA) ) has provided an announcement.

On June 23, 2025, Sana Biotechnology announced positive six-month clinical results from a study transplanting UP421, an allogeneic primary islet cell therapy using their hypoimmune technology, into a patient with type 1 diabetes without immunosuppression. The study, conducted with Uppsala University Hospital, showed that the transplanted cells survived, functioned, and evaded immune detection, marking a potential breakthrough in diabetes treatment. This development could transform cellular medicine by providing a therapy that allows for normal blood glucose control without insulin or immunosuppression, potentially benefiting over nine million people globally affected by type 1 diabetes.

The most recent analyst rating on (SANA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Sana Biotechnology stock, see the SANA Stock Forecast page.

Spark’s Take on SANA Stock

According to Spark, TipRanks’ AI Analyst, SANA is a Underperform.

Sana Biotechnology’s overall stock score is primarily impacted by significant financial challenges, including consistent losses and a lack of revenue. Despite some improvements in balance sheet stability and operating cash flow, the bearish technical indicators and negative valuation metrics underscore the need for strategic changes to achieve growth and profitability.

To see Spark’s full report on SANA stock, click here.

More about Sana Biotechnology

Sana Biotechnology, Inc. is a company focused on creating and delivering engineered cells as medicines for patients, with a vision of repairing and controlling genes and replacing missing or damaged cells.

Average Trading Volume: 3,830,125

Technical Sentiment Signal: Sell

Current Market Cap: $588.7M

See more data about SANA stock on TipRanks’ Stock Analysis page.